Press Releases & Awards Archives | MicroGen Diagnostics

January 24, 2018

Dr. Dean Tortorelis (at left) and Dr. Joseph Cerny

January 24, 2018

More than meets the eye: Innovative technology spots bacteria previously undetected

Two Robbinsdale urologists leading the way regionally in treating chronic infections By LACI GAGLIANO [email protected] Two physicians in the Urology Associates group at North Memorial Health Hospital, Dr. Joseph Cerny and Dr. Dean Tortorelis, have harnessed cutting-edge technology, used by National Aeronautics and Space Administration on the Martian Rover, to get a leg up on hidden strains of bacteria that are responsible for recurrent urinary tract and prostate infections. The science behind the technology is far more earthbound than it sounds. Based in a laboratory in Lubbock, Texas, MicroGenDX is the innovative testing technology that has enabled Cerny and Tortorelis […]

May 16, 2019

May 16, 2019

MicroGenDX’s Next-Generation DNA Sequencing Ushers in New Era of Advanced Infection Diagnostics at 2019 American Academy of Orthopedic Surgeons with Multiple Podium Talks

MicroGenDX, the world leader in Next Generation DNA Sequencing (NGS) in microbial identification took the podium an unprecedented three times at the largest and most reputable orthopedic conference in the world held by the American Academy of Orthopedic Surgeons (AAOS).

February 7, 2020

MicroGenDX Next-Generation DNA Sequencing to Take Center Stage at American Association of Hip and Knee Surgeons to Reveal New Findings in Periprosthetic Joint Infection

MicroGenDX Laboratories equipped a multicenter study with its gold standard NGS test to investigate the persistence of Periprosthetic Joint Infection (PJI). Renowned orthopedic surgeon Javad Parvizi, MD will take the podium at American Association of Hip and Knee Surgeons (AAHKS) to discuss results of the study to show how NGS is revolutionizing the microbial diagnosis of chronic infections in orthopedics. Click Here to Read Full Article…

February 7, 2020

MicroGenDX Next-Gen DNA Sequencing Used in Breakthrough Knee Infection Study: Rothman Institute Accepts Eastern Orthopaedic Association’s Musculoskeletal Infection Award

MicroGenDX, the world leader in providing Next Generation DNA Sequencing (NGS) in microbial identification, processed samples in the groundbreaking study “Next Generation Sequencing for the Diagnosis of Periprosthetic Knee Infection: A Multicenter Investigation” led by the Rothman Institute. The study recently accepted the Eastern Orthopaedic Association’s Musculoskeletal Infection Award and further evidenced that advanced molecular diagnostic testing gives hope to patients suffering from devastating chronic infections. Click Here to Read Full Article…

August 25, 2020

August 25, 2020

MicroGenDX is NOT under investigation by the FDA and is in good standing with CAP (the College of American Pathologists)

MicroGenDX, a high complexity lab based out of Florida, is not under investigation by the FDA and is, and always has been, in good standing with the College of American Pathologists. The purpose of this post is to address concerns arising from false and inaccurate information that is contained within an article titled FDA investigates lab as tens of thousands of COVID-19 test results in Florida are questioned, published on May 21, 2020 and updated on July 22, 2020 by USAToday.com and other websites. This article has been promoted through social media by competitors of MicroGenDX, and others with agendas […]

September 15, 2020

Next Generation Sequencing Predicts Failure in Total Joint Arthroplasty

Disruptive new multicenter research has determined that next generation sequencing (NGS) can reliably predict treatment failure due to periprosthetic joint infection (PJI). MicroGenDX, the High Complexity Laboratory utilized in the study, is upending outdated approaches to infection detection, instead relying on the most up-to-date technologies to not only determine that an infection is present, but to identify the exact micro-organism(s) involved.

April 6, 2021

MicroGenDX announces SARS-CoV-2 Whole Genome Variant Identification

New variants continue to emerge rapidly around the globe, causing sequencing efforts at health departments and universities to surveil a small portion of the population and, in some cases, limit their sequencing efforts to breakthrough cases. MicroGenDX is proud to offer the first commercially available, quick-turnaround, economical and accurate option for SARS-CoV-2 whole genome sequencing to combat the spread of emerging variants and gain a better understanding of the epidemiology of SARS-CoV-2.

May 14, 2021

MicroGenDX Selected for 2022 Israeli Space Mission Study

“We’re honored and excited to be part of this study to evaluate the impact of space travel on the urinary microbiome,” says Rick Martin, CEO of MicroGenDX. “MicroGenDX is uniquely qualified to provide this data for analysis that could be the basis for future solutions to astronaut medical care. This work will help shape the future of long-term space missions — including the multi-year Mars mission.”

May 24, 2021

MicroGenDX is Introducing PerioDX, the First Commercially Available Saliva-Based qPCR+NGS Test for Oral Health

MicroGen Diagnostics, the industry leader in providing next-generation DNA sequencing (NGS) for clinical diagnostics, announces its entry into oral microbial diagnostics with the PerioDX test. PerioDX is the first commercially available saliva-based periodontal test to combine quantitative polymerase chain reaction (qPCR) and NGS technology for comprehensive DNA diagnostic results. PerioDX identifies 17 antibiotic resistance genes and all clinically relevant microbes in a sample,1 thereby assisting clinicians both with treatment choices and promoting antimicrobial stewardship. Click Here to Read Full Article…

May 25, 2021

MicroGenDX Announces OrthoKEY® Infection Diagnosis and Management for Periprosthetic Joint Infection

ORLANDO, Fla., May 24, 2021 /PRNewswire/ — MicroGen Diagnostics, the industry leader in providing next-generation DNA sequencing (NGS) for clinical diagnostics, has introduced OrthoKEY, an innovative approach to address current clinical shortcomings in the diagnosis of orthopedic infections. OrthoKEY brings accuracy, sensitivity, timeliness, and affordability to PJI diagnostics and management for the clinic and operating room.…

September 1, 2021

MicroGenDX Announces Acquisition of RTL Genomics to Advance Primary Research in DNA Sequencing

ORLANDO, Fla., Sep 1, 2021 /PRNewswire/ — MicroGen Diagnostics, the industry leader in providing Next-Generation DNA Sequencing (NGS) for clinical diagnostics, has acquired its RTL Genomics partner lab to expand expertise and capacity in non-clinical primary research.…

September 10, 2021

MicroGenDX Resolves Dispute with AdventHealth over COVID-19 Testing Services

ORLANDO, Fla., May 24, 2021 /PRNewswire/ — MicroGen Diagnostics (MicroGenDX) is pleased to announce that it has resolved a dispute with AdventHealth concerning Covid-19 testing services that were provided to AdventHealth during the height of the global pandemic in May of 2020.…